pcDNA3.3-SARS2-B.1.617.2 Citations (21)
Originally described in: Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J Sci Transl Med. 2021 Oct 20;13(616):eabj5413. doi: 10.1126/scitranslmed.abj5413. Epub 2021 Oct 20. PubMed Journal
Articles Citing pcDNA3.3-SARS2-B.1.617.2
| Articles |
|---|
| LRRC15 is an inhibitory receptor blocking SARS-CoV-2 spike-mediated entry in trans. Song J, Chow RD, Pena-Hernandez M, Zhang L, Loeb SA, So EY, Liang OD, Wilen CB, Lee S. bioRxiv. 2021 Nov 24. doi: 10.1101/2021.11.23.469714. PubMed |
| Targeting an evolutionarily conserved "E-L-L" motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2. Jana ID, Bhttacharya P, Mayilsamy K, Banerjee S, Bhattacharje G, Das S, Aditya S, Ghosh A, McGill AR, Srikrishnan S, Das AK, Basak A, Mohapatra SS, Chandran B, Bhimsaria D, Mohapatra S, Roy A, Mondal A. bioRxiv. 2022 Mar 21. doi: 10.1101/2022.03.16.484554. PubMed |
| Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody. Sulea T, Baardsnes J, Stuible M, Rohani N, Tran A, Parat M, Cepero Donates Y, Duchesne M, Plante P, Kour G, Durocher Y. PLoS One. 2022 Mar 30;17(3):e0266250. doi: 10.1371/journal.pone.0266250. eCollection 2022. PubMed |
| SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Shah M, Ung Moon S, Hyun Kim J, Thanh Thao T, Goo Woo H. Comput Struct Biotechnol J. 2022;20:2042-2056. doi: 10.1016/j.csbj.2022.04.030. Epub 2022 Apr 26. PubMed |
| High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1. Kuzikov M, Woens J, Zaliani A, Hambach J, Eden T, Fehse B, Ellinger B, Riecken K. Biomed Pharmacother. 2022 Jul;151:113104. doi: 10.1016/j.biopha.2022.113104. Epub 2022 May 16. PubMed |
| Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. Chiu CH, Chang YH, Chang FY, Hung YJ, Liao CL, Chiu KC, Tsai PL, Chang TW, Yen LC. Front Cell Infect Microbiol. 2022 May 17;12:862656. doi: 10.3389/fcimb.2022.862656. eCollection 2022. PubMed |
| Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Vikkurthi R, Ansari A, Pai AR, Jha SN, Sachan S, Pandit S, Nikam B, Kalia A, Jit BP, Parray HA, Singh S, Kshetrapal P, Wadhwa N, Shrivastava T, Coshic P, Kumar S, Sharma P, Sharma N, Taneja J, Pandey AK, Sharma A, Thiruvengadam R, Grifoni A, Weiskopf D, Sette A, Bhatnagar S, Gupta N. Nat Microbiol. 2022 Jul;7(7):974-985. doi: 10.1038/s41564-022-01161-5. Epub 2022 Jun 9. PubMed |
| Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. Duan LJ, Jiang WG, Wang ZY, Yao L, Zhu KL, Meng QC, Wang BS, Li LB, Wang GL, Ma MJ. iScience. 2022 Sep 16;25(9):104886. doi: 10.1016/j.isci.2022.104886. Epub 2022 Aug 9. PubMed |
| Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH, Chang YH, Tao CW, Chang FY, Chiu KC, Chang TW, Yen LC. Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25. PubMed |
| LRRC15 inhibits SARS-CoV-2 cellular entry in trans. Song J, Chow RD, Pena-Hernandez MA, Zhang L, Loeb SA, So EY, Liang OD, Ren P, Chen S, Wilen CB, Lee S. PLoS Biol. 2022 Oct 13;20(10):e3001805. doi: 10.1371/journal.pbio.3001805. eCollection 2022 Oct. PubMed |
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.
Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J.
Cell Host Microbe. 2022 Nov 4. pii: S1931-3128(22)00523-6. doi: 10.1016/j.chom.2022.10.010.
PubMed
Associated Plasmids |
| Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen. Azuma H, Kawano Y, Shitaoka K, Kawahara T, Ito A, Higashiura A, Kitajima Y, Ohki S, Yasuda T. Int Immunol. 2023 Apr 4;35(4):197-207. doi: 10.1093/intimm/dxac055. PubMed |
| Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. Xiang Y, Zhai G, Li Y, Wang M, Chen X, Wang R, Xie H, Zhang W, Ge G, Zhang Q, Xu Y, Caflisch A, Xu J, Chen H, Chen L. Int J Biol Macromol. 2023 Jan 31;226:780-792. doi: 10.1016/j.ijbiomac.2022.12.057. Epub 2022 Dec 12. PubMed |
| Inhibitory Activity of Saussurea costus Extract against Bacteria, Candida, Herpes, and SARS-CoV-2. Idriss H, Siddig B, Gonzalez-Maldonado P, Elkhair HM, Alakhras AI, Abdallah EM, Elzupir AO, Sotelo PH. Plants (Basel). 2023 Jan 19;12(3):460. doi: 10.3390/plants12030460. PubMed |
| Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. Shitaoka K, Higashiura A, Kawano Y, Yamamoto A, Mizoguchi Y, Hashiguchi T, Nishimichi N, Huang S, Ito A, Ohki S, Kanda M, Taniguchi T, Yoshizato R, Azuma H, Kitajima Y, Yokosaki Y, Okada S, Sakaguchi T, Yasuda T. Commun Biol. 2023 Apr 11;6(1):395. doi: 10.1038/s42003-023-04782-6. PubMed |
| The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection. Bains A, Guan W, LiWang PJ. Viruses. 2023 Sep 9;15(9):1901. doi: 10.3390/v15091901. PubMed |
| Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage. Shukla N, Roelle SM, Snell JC, DelSignore O, Bruchez AM, Matreyek KA. bioRxiv [Preprint]. 2024 Feb 14:2024.02.13.580056. doi: 10.1101/2024.02.13.580056. PubMed |
| Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand. Chawansuntati K, Sakkhachornphop S, Hongjaisee S, Freeouf S, Sripan P, Nusartsang N, Chaiwarith R, Sudjaritruk T, Supparatpinyo K, Wipasa J. Vaccine X. 2024 Mar 16;18:100475. doi: 10.1016/j.jvacx.2024.100475. eCollection 2024 Jun. PubMed |
| Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants. Thummler L, Beckmann N, Sehl C, Soddemann M, Brass P, Bormann M, Brochhagen L, Elsner C, Hoertel N, Cougoule C, Ciesek S, Widera M, Dittmer U, Lindemann M, Horn PA, Witzke O, Kadow S, Kamler M, Gulbins E, Becker KA, Krawczyk A. Viruses. 2024 Mar 30;16(4):545. doi: 10.3390/v16040545. PubMed |
Pseudotyped virus infection of multiplexed ACE2 libraries reveals SARS-CoV-2 variant shifts in receptor usage.
Shukla N, Roelle SM, Snell JC, DelSignore O, Bruchez AM, Matreyek KA.
PLoS Pathog. 2024 May 20;20(5):e1012044. doi: 10.1371/journal.ppat.1012044.
PubMed
Associated Plasmids |
| Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays. Manu AA, Owusu IA, Oyawoye FO, Languon S, Barikisu IA, Tawiah-Eshun S, Quaye O, Donkor KJ, Paemka L, Amegatcher GA, Denyoh PMD, Oduro-Mensah D, Awandare GA, Quashie PK. Heliyon. 2024 May 19;10(10):e31392. doi: 10.1016/j.heliyon.2024.e31392. eCollection 2024 May 30. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.